Medicinal chemistry of catechol O -methyltransferase (COMT) inhibitors and their therapeutic utility

Journal of Medicinal Chemistry

Volumn 57, Issue 21, 2014, Pages 8692-8717

  Kiss, László E ^a   Soares Da Silva, Patrício ^a,b,c  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYESTRADIOL; 2 HYDROXYESTRONE; 3',4' DIHYDROXY 2 METHYLPROPIOPHENONE; 3,4 DIHYDROXYMANDELIC ACID; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXYESTRADIOL; APOMORPHINE; ASCORBIC ACID; BENSERAZIDE; CAFFEIC ACID; CARBIDOPA; CATECHOL; CATECHOL DERIVATIVE; CATECHOL ESTROGEN; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOBUTAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; FENOLDOPAM; ISOPRENALINE; LEVODOPA; METHYLDOPA; NITECAPONE; NORADRENALIN; PROTOCATECHUIC ACID; QUERCETIN; RIMITEROL; UNINDEXED DRUG; ACETOPHENONE DERIVATIVE; NEBICAPONE; NITRILE; OPICAPONE; OXADIAZOLE DERIVATIVE; PRODRUG;

ANALGESIA; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CENTRAL NERVOUS SYSTEM DISEASE; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ELIMINATION HALF-LIFE; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME SUBSTRATE; HUMAN; IC50; MEDICINAL CHEMISTRY; MENTAL PATIENT; MOLECULAR RECOGNITION; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; PHYSICAL CHEMISTRY; PROTEIN METHYLATION; PSYCHOSIS; SCHIZOPHRENIA; ANIMAL; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); MALE; METABOLISM; RAT; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ACETOPHENONES; ANIMALS; CATALYSIS; CATECHOL O-METHYLTRANSFERASE; CATECHOL O-METHYLTRANSFERASE INHIBITORS; CATECHOLS; CLINICAL TRIALS AS TOPIC; CRYSTALLOGRAPHY, X-RAY; HUMANS; INHIBITORY CONCENTRATION 50; LEVODOPA; MALE; MODELS, MOLECULAR; NITRILES; OXADIAZOLES; PARKINSON DISEASE; PRODRUGS; RATS;

EID: 84923796794     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500572b     Document Type: Article

References (179)

1. Armstrong, M. D.; McMillan, A.; Shaw, K. N. F. 3-Methoxy-4-hydroxy-D-mandelic acid, a urinary metabolite of norepinephrine Biochim. Biophys. Acta 1957, 25, 422-423
2. Axelrod, J.; Tomchick, R. Enzymatic O -methylation of epinephrine and other catechols J. Biol. Chem. 1958, 233, 702-705
3. Axelrod, J.; Senoh, S.; Witkop, B. O -Methylation of catecholamines in vivo J. Biol. Chem. 1958, 233, 697-701
4. Bacq, Z. M.; Gosselin, L.; Dresse, A.; Renson, J. Inhibition of O-methyltransferase by catechol and sensitization to epinephrine Science 1959, 130, 453-454
5. Calne, D. B. Treatment of Parkinsons disease N. Engl. J. Med. 1993, 329, 1021-1027
6. Kaakkola, S.; Gordin, A.; Jarvinen, M.; Wikberg, T.; Schultz, E.; Nissinen, E.; Pentikainen, P. J.; Rita, H. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-Dopa in healthy volunteers Clin. Neuropharmacol. 1990, 13, 436-447
7. Keranen, T.; Gordin, A.; Karlson; Wikberg, T. Inhibition of soluble catechol O -methyltranferse and single dose pharmacokinetics after oral and intraveneus administration of entacapone Eur. J. Clin. Pharmacol. 1994, 46, 151-157
8. Dingemanse, J.; Jorga, K. M.; Schmitt, M.; Gieschke, R.; Fotteler, B.; Zürcher, G.; Da Prada, M.; van Brummelen, P. Integrated pharmacokinetics and pharmacodynamics of the novel catechol- O -methyltransferase inhibitor tolcapone during first administration to humans Clin. Pharmacol. Ther. 1995, 57, 508-517
9. Ferreira, J.; Rosa, M. M.; Coelho, M.; Cunha, L.; Januario, C.; Machado, C.; Morgadinho, A.; Ticmeanu, M.; Mitu, C.-E.; Novac, M. A double-blind, randomised, placebo- and entacapone-controlled study to investigate the effect of nebicapone (BIA 3-202) on the levodopa pharmacokinetics, COMT activity and motor response in Parkinson disease patients Mov. Disord. 2006, 21 (Suppl. 15) S644-S645
10. Almeida, L.; Rocha, J. F.; Falcão, A.; Nuno Palma, P.; Loureiro, A. I.; Pinto, R.; Bonifacio, M. J.; Wright, L. C.; Nunes, T.; Soares-da-Silva, P. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-o-methyltransferase inhibitor, in healthy subjects: Prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor Clin. Pharmacokinet. 2013, 52, 139-151
11. Axelrod, J. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines Pharmacol. Rev. 1966, 18, 95-113
12. Crevelimg, C. R.; Dalgard, N.; Shimizu, H.; Daly, J. W. Catechol O -methyltransferase: III. m-and p-O -methylation of catecholamines and their metabolites Mol. Pharmacol. 1970, 6, 691-696
13. Vidgren, J.; Svensson, L. A.; Liljas, A. Crystal structure of catechol- O -methyltransferase Nature 1994, 368, 354-358
14. Masri, M. S.; Robbins, D. J.; Emerson, O. H.; Deeds, F. Selective para- or meta-O -methylation with catechol O -methyl transferase from rat liver Nature 1964, 202, 878-879
15. Guldberg, H. C.; Marsden, C. A. Catechol- O -methyltransferase: Pharmacological aspects and physiological role Pharmacol. Rev. 1975, 27, 135-206
16. Zhu, B. T.; Ezell, E. L.; Liehr, J. G. Catechol- O -methyltransferase-catalysed rapid O -methylation of mutagenic flavanoids. metabolic inactivation as a possible reason for their lack of carcinogenicity in vivo J. Biol. Chem. 1994, 269, 292-299
17. Burba, J. V.; Becking, G. C. Effect of the antioxidant norhydroguaiaretic acid on the in vitro activity of catechol- O -methyltransferase Arch. Int. Pharmacodyn. Ther. 1969, 180, 323-329
18. Porter, C. C.; Watson, L. S.; Titus, D. C.; Totaro, J. A.; Byer, S. S. Inhibition of DOPA decarboxylase by the hydrazino analog of alpha-methylDOPA Biochem. Pharmacol. 1962, 11, 1067-1077
19. Burkard, W. P.; Gey, K. F.; Pletscher, A. A new inhibitor of decarboxylase of aromatic amino acids Experientia 1962, 18, 411-412
20. Muguet, D.; Broussolle, E.; Chazot, G. Apomorphine in patients with Parkinsons disease Biomed. Pharmacother. 1995, 49, 197-209
21. Sonnenblick, E. H.; Frishman, W. H.; LeJemiel, T. H. Dobutamine: A new synthetic cardioactive sympathetic amine N. Engl. J. Med. 1979, 300, 17-22
22. Caruana, M. P.; Heber, M.; Brigden, G.; Raftery, E. B. Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension Br. J. Clin. Pharmacol. 1984, 24, 721-727
23. Frohlich, E. D. Methyldopa. Mechanisms and treatment 25 years later Arch. Int. Med. 1980, 140, 954-959
24. Popa, V. T. Clinical pharmacology of adrenergic drugs J. Asthma 1984, 21, 183-207
25. Bowman, W. c.; Rodger, I. W. Actions of the sympathomimetic bronchodilator, rimiterol (R798), on the cardiovascular, respiratory and skeletal muscle systems of the anaesthetized cat Br. J. Pharmacol. 1972, 45, 574-583
26. Miyöhänen, T. T.; Schendzielorz, N.; Männistö, P. T. Distribution of catechol- O -methyltransferase (COMT) proteins and enzymatic activities in wild-type and S-COMT deficient mice J. Neurochem. 2010, 113, 1632-1643
27. Ellingson, T.; Duddempudi, S.; Greenberg, B. D.; Hooper, D.; Eisenhofer, G. Determination of differential activities of soluble and mebrane-bound catechol-O-methyltransferase in tissues and erythrocytes J. Chromatogr. B: Biomed. Sci. Appl. 1999, 1-2, 347-353
28. Borchardt, R. T.; Cheng, C.-F.; Cooke, P. H. The purification and kinetic properties of liver microsomal-catechol-O-methyltransferase Life Sci. 1974, 14, 1089-1100
29. Tenhunen, J.; Salminen, M.; Jalanko, A.; Ukkonen, S.; Ulmanen, I. Structure of the rat catechol- O -methyltransferase gene: Separate promoters are used to produce mRNAs for soluble and membrane-bound forms of the enzyme DNA Cell Biol. 1993, 12, 253-263
30. Grossman, M. H.; Emanuel, B. S.; Budarf, M. L. Chromosomal mapping of the human catechol- O -methyltransferase gene to 22q11.1→q11.2 Genomics 1992, 12, 822-825
31. Lotta, T.; Vidgren, J.; Tilgmann, C.; Ulmanen, I.; Melén, K.; Julkunen, I.; Taskinen, J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme Biochemistry 1995, 34, 4202-4210
32. Karhunen, T.; Tilgmann, C.; Ulmanen, I.; Julkunen, I.; Panula, P. Distribution of catechol- O -methyltransferase enzyme in rat tissues J. Histochem. Cytochem. 1994, 42, 1079-1090
33. Roth, J. A. Membrane-bound catechol-O-methyltransferase: A re-evaluation of its role in the O-methylation of catecholamine neurotransmitters Rev. Physiol. Biochem. Pharmacol. 1992, 120, 1-29
34. Huotari, M.; Gogos, J. A.; Karayiorgou, M.; Koponen, O.; Forsberg, M.; Raasmaja, A.; Hyttinen, J.; Männistö, P. T. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice Eur. J. Neurosci. 2002, 15, 246-256
35. Coward, J. K.; Slixz, E. P.; Wu, F. Y. Kinetic studies on catechol O-methyltransferase: Product inhibition and the nature of the catechol binding site Biochemistry 1973, 12, 2291-2297
36. Woodard, R. W.; Tsai, M. D.; Floss, H. G.; Crooks, P. A.; Coward, J. K. Stereochemical course of the transmethylation catalyzed by catechol-O-methyltransferase J. Biol. Chem. 1980, 255, 9124-9127
37. Borgulya, J.; Bruderer, H.; Bernauer, K.; Zurcher, G.; Da Prada, M. Catechol- O -methyltransferase-inhibiting pyrocatechol derivatives: Synthesis and structure-activity studies Helv. Chim. Acta 1989, 72, 952-968
38. Vidgren, J.; Tilgmann, C.; Lundström, K.; Liljas, A. Crystallisation and preliminary X-ray investigation of a recombinant form of rat catechol- O -methyltransferase Proteins 1991, 11, 233-236
39. Ma, Z.; Liu, H.; Wu, B. Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders Br. J. Clin. Pharmacol. 2013, 77, 410-420
40. Rutherford, K.; Le Trong, I.; Stenkamp, R. E.; Parson, W. W. Crystal structures of human 108V and 108M catechol O-methyltransferase J. Mol. Biol. 2008, 380, 120-130
41. Piedrafita, F. J.; Elorriaga, C.; Fernández-Alvarez, E.; Nieto, O. Inhibition of catechol-O-methyltransferase by N -(3,4-dihydroxyphenyl) maleimide J. Enzyme Inhib. 1990, 4, 43-50
42. Jatana, N.; Apoorva, N.; Malik, Sonika; Sharma, A.; Latha, N. Inhibitors of catechol-O-methyltransferase in the treatment of neurological disorders Cent. Nerv. Syst. Agents Med. Chem. 2013, 13, 166-194
43. Männistö, P. T.; Kaakkola, S. New selective COMT inhibitors: useful adjuncts for Parkinsons disease? Trends Pharmacol. Sci. 1989, 10, 54-56
44. Sharif, A. A. Entacapone in restless legs syndrome Mov. Disord. 2002, 17, 421
45. Egan, M. F.; Goldberg, T. E.; Kolachana, B. S.; Callicott, J. H.; Mazzanti, C. M.; Straub, R. E.; Goldman, D.; Weinberger, D. R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia Proc. Natl. Acad. Sci. USA 2001, 98, 6917-6922
46. Fava, M.; Rosenbaum, J. F.; Kolsky, A. R.; Alpert, J. E.; Nierenberg, A. A.; Spillmann, M.; Moore, C.; Renshaw, P.; Bottiglieri, T.; Moroz, G.; Magni, G. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder J. Clin. Psychopharmacol. 1999, 19, 329-335
47. Lachman, H. M.; Papolos, D. F.; Saito, T.; Yu, Y. M.; Szumlanski, C. L.; Weinshilboum, R. M. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders Pharmacogenetics 1996, 6, 243-250
48. Berk, M.; Dodd, S.; Kauer-SantAnna, M.; Malhi, G. S.; Bourin, M.; Kapczinski, F.; Norman, T. Dopamine dysregulation syndrome: Implications for a dopamine hypothesis of bipolar disorder Acta Psychiatr. Scand. 2007, 116, 41-49
49. Vieira-Coelho, M. A.; Gomes, P.; Serrão, M. P.; Soares-da-Silva, P. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors Kidney Int. 2001, 59, 1683-1694
50. Larsen, K. R.; Dajani, E. Z.; Dajani, N. E.; Dayton, M. T.; Moore, J. G. Effects of tolcapone, a catechol- O -methyltransferase inhibitor, and sinemet on intestinal electrolyte and fluid transport in conscious dogs Dig. Dis. Sci. 1998, 43, 1806-1813
51. Talan, J. Attention deficit disorder associated with dopamine deficits in brain Neurol. Today 2009, 9, 10
52. DiMaio, S.; Grizenko, N.; Joober, R. Dopamine genes and attention-deficit hyperactivity disorder: A review J. Psychiatry Neurosci. 2003, 28, 27-38
53. Orth, M.; Schapira, A. H. Mitochondrial involvement in Parkinsons disease Neurochem. Int. 2002, 40, 533-541
54. Kopin, I. J. Monoamine oxidase and catecholamine metabolism J. Neural Transm., Suppl. 1994, 41, 57-67
55. Birkmayer, W.; Hornykiewicz, O. Der L-3,4-dioxyphenylalanin (L-DOPA)-effekt bei der Parkinson-akinese Wien. Klin. Wochenschr. 1961, 73, 787-788
56. Rinne, U. K.; Molsa, P. Levodopa with benserazide or carbidopa in Parkinson disease Neurology 1979, 29, 1584-1589
57. Nutt, J. G.; Fellman, J. H. Pharmacokinetics of levodopa Clin. Neuropharmacol. 1984, 7, 35-39
58. Kuruma, I.; Bartholini, G.; Tissot, R.; Pletscher, A. The metabolism of L-3- O -methyldopa, a precursor dopa in man Clin. Pharmacol. Ther. 1971, 12, 678-682
59. Nutt, J. G.; Woodward, W. R.; Beckner, R. M.; Stone, C. K.; Berggren, K.; Carter, J. H.; Gancher, S. T.; Hammerstad, J. P.; Gordin, A. Effect of peripheral catechol- O -methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients Neurology 1994, 44, 913-919
60. Green, A. E.; Kraemer, D. J.; Deyoung, C. G.; Fossella, J. A.; Gray, J. R. A gene-brain-cognition pathway: Prefrontal activity mediates the effect of COMT on cognitive control and IQ Cereb. Cortex 2013, 23, 552-559
61. Apud, J. A.; Weinberger, D. R. Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors CNS Drugs 2007, 21, 535-557
62. Talkowski, M. E.; Kirov, G.; Bamne, M.; Georgieva, L.; Torres, G.; Mansour, H.; Chowdari, K. V.; Milanova, V.; Wood, J.; McClain, L.; Prasad, K.; Shirts, B.; Zhang, J.; ODonovan, M. C.; Owen, M. J.; Devlin, B.; Nimgaonkar, V. L. A network of dopaminergic gene variations implicated as risk factors for schizophrenia Hum. Mol. Genet. 2008, 17, 747-758
63. Williams, H. J.; Owen, M. J.; ODonovan, M. C. Is COMT a susceptibility gene for schizophrenia? Schizophr. Bull. 2007, 33, 635-641
64. Caramona, M. M.; Soares-da-Silva, P. The effects of chemical sympathectomy on dopamine, noradrenaline and adrenaline content in some peripheral tissues Br. J. Pharmacol. 1985, 86, 351-356
65. Soares-da-Silva, P. Evidence for dopaminergic co-transmission in dog mesenteric arterial vessels Br. J. Pharmacol. 1988, 95, 218-224
66. Vieira-Coelho, M. A.; Gomes, P.; Serrão, M. P.; Soares-da-Silva, P. Renal and intestinal autocrine monoaminergic systems: Dopamine versus 5-hydroxytryptamine Clin. Exp. Hypertens. 1997, 19, 43-58
67. Jose, P. A.; Soares-da-Silva, P.; Eisner, G. M.; Felder, R. A. Dopamine and G protein-coupled receptor kinase 4 in the kidney: Role in blood pressure regulation Biochim. Biophys. Acta 2010, 1802, 1259-1267
68. Helkamaa, T.; Männistö, P. T.; Rauhala, P.; Cheng, Z. J.; Finckenberg, P.; Huotari, M.; Gogos, J. A.; Karayiorgou, M.; Mervaala, E. M. Resistance to salt-induced hypertension in catechol-O-methyltransferase-gene-disrupted mice J. Hypertens. 2003, 21, 2365-2374
69. Helkamaa, T.; Finckenberg, P.; Louhelainen, M.; Merasto, S.; Rauhala, P.; Lapatto, R.; Cheng, Z. J.; Reenila, I.; Männistö, P. T.; Müller, D. N.; Luft, F. C.; Mervaala, E. M. Entacapone protects from angiotensin II-induced inflammation and renal injury J. Hypertens. 2003, 21, 2353-2363
70. Eriksson, A. L.; Skrtic, S.; Niklason, A.; Hultén, L. M.; Wiklund, O.; Hedner, T.; Ohlsson, C. Association between the low activity genotype of catechol-O-methyltransferase and myocardial infarction in a hypertensive population Eur. Heart J. 2004, 25, 386-391
71. Hagen, K.; Pettersen, E.; Stovner, L. J.; Skorpen, F.; Holmen, J.; Zwart, J. A. High systolic blood pressure is associated with Val/Val genotype in the catechol- O -methyltransferase gene. The Nord-Trondelag Health Study (HUNT) Am. J. Hypertens. 2007, 20, 21-26
72. Htun, N. C.; Miyaki, K.; Song, Y.; Ikeda, S.; Shimbo, T.; Muramatsu, M. Association of the catechol-O-methyl transferase gene Val158Met polymorphism with blood pressure and prevalence of hypertension: interaction with dietary energy intake Am. J. Hypertens. 2011, 24, 1022-1026
73. Friese, R. S.; Schmid-Schonbein, G. W.; OConnor, D. T. Systematic polymorphism discovery after genome-wide identification of potential susceptibility loci in a hereditary rodent model of human hypertension Blood Press. 2011, 20, 222-231
74. Flemström, G.; Safsten, B.; Jedstedt, G. Stimulation of mucosal alkaline secretion in rat duodenum by dopamine and dopaminergic compounds Gastroenterology 1993, 104, 825-833
75. Li, L. S.; Zheng, L. F.; Xu, J. D.; Ji, T.; Guo, H.; Li, X. F.; Li, Y.; Zhang, Y.; Zhu, J. X. Entacapone promotes cAMP-dependent colonic Cl(-) secretion in rats Neurogastroenterol. Motil. 2011, 23, 657-e277
76. Tahara, T.; Shibata, T.; Nakamura, M.; Yoshioka, D.; Okubo, M.; Maruyama, N.; Kamano, T.; Kamiya, Y.; Fujita, H.; Nagasaka, M.; Iwata, M.; Takahama, K.; Watanabe, M.; Yamashita, H.; Nakano, H.; Hirata, I.; Arisawa, T. COMT gene Val158Met polymorphism influences the severity of intestinal metaplasia in H. pylori infected older subjects Hepatogastroenterology 2009, 56, 411-415
77. Palma, P. N.; Kiss, L. E.; Soares-da-Silva, P. Catechol- O -methyl-transferase inhibitors: Present problems and relevance of the new ones. In Emerging Drugs and Targets for Parkinsons Disease; Martinez, A.; Gil, C., Eds.; RSC Publishing: Cambridge, U.K., 2013; pp 83-109.
78. Learmonth, D. A.; Kiss, L. E.; Soares-da-Silva, P. Chemistry of COMT Inhibitors. In Basic Aspects of Catechol-O-methyltransferase and the Clinical Applications of Its Inhibitors; Nissinen, E., Ed.; Elsevier: Amsterdam, 2010; pp 119-162.
79. Masri, M. S.; Booth, A. N.; Deeds, F. O-Methylation in vitro of dihydroxy- and trihydroxy-phenolic compounds by liver slices Biochim. Biophys. Acta 1962, 65, 495-505
80. Gugler, R.; Dengler, H. J. Inhibition of liver catechol-O-methyltransferase by flavanoids Naunyn-Schmiedebergs Arch. Pharmacol. 1973, 276, 223-233
81. Giles, R. E.; Miller, J. W. The catechol-O-methyltransferase activity and endogenous catecholamine content of various tissues in the rat and the effect of administration of U-0521 (3,4-dihydroxy-2-methylpropiophenone) J. Pharmacol. Exp. Ther. 1967, 158, 189-194
82. Ross, S. B.; Haljasmaa, O. Catechol-O-methyltransferase inhibitors. In vivo inhibition in mice Acta. Pharmacol. Toxicol. 1964, 21, 215-225
83. Angel, A.; Rogers, K. J. Convulsant action of polyphenols Nature 1968, 217, 84-85
84. Reches, A.; Fahn, S. Catechol-O-methyltransferase and Parkinsons disease Adv. Neurol. 1984, 40, 171
85. Archer, S.; Arnold, A.; Kullnig, R. K.; Wylie, D. The enzymic methylation of pyrogallol Arch. Biochem. Biophys. 1960, 87, 53-154
86. Axelrod, J.; LaRoche, M.-J. Inhibitor of O-methylation of epinephrine and norepinephrine in vitro and in vivo Science 1959, 130, 800
87. Booth, A. N.; Masri, M.; Robbins, D. J.; Emerson, O. H.; Jones, F. T.; Deeds, F. The metabolic fate of gallic acid and related compounds J. Biol. Chem. 1959, 234, 3014-3016
88. Ericson, A. D. Potentiation of the L-dopa effect in man by the use of catechol- O -methyltransferase inhibitors J. Neurol. Sci. 1971, 24, 193-197
89. Simpson, G. M.; Varga, V. An investigation of the clinical effect of GPA-1714, a catechol-O-methyl transferase inhibitor J. Clin. Pharmacol. 1972, 12, 417-421
90. Bäckström, R.; Honkanen, E.; Pippuri, A.; Kairisalo, P.; Pystynen, J.; Heinola, K.; Nissinen, E.; Lindén, I.-B.; Männistö, P. T.; Kaakkola, S.; Pohto, P. Synthesis of some novel potent and selective catechol O -methyltransferase inhibitors J. Med. Chem. 1989, 32, 841-846
91. Bäckström, R. J.; Heinola, K. E.; Honkanen, E. J.; Kaakkola, S. K.; Kairisalo, P. J.; Linden, I.-B. Y.; Männistö, P. T.; Nissinen, E. A. O.; Pohto, P.; Pippuri, A. K.; Pystynen, J. J. Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same. U.S. Patent US4963590, 1990.
92. Nissinen, E.; Linden, I. B.; Schultz, E.; Kaakkola, S.; Männistö, P. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat Eur. J. Pharmacol. 1988, 153, 263-269
93. Schultz, E.; Nissinen, E. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462 Biochem. Pharmacol. 1989, 38, 3953-3956
94. Männistö, P.; Tuomainen, T.; Tuomainen, R. K. Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat Br. J. Pharmacol. 1992, 105, 569-574
95. Cedarbaum, J.; Leger, G.; Reches, A.; Guttman, M. Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys Clin. Neuropharmacol. 1990, 13, 544-552
96. Nissinen, E.; Linden, I. B.; Schultz, E.; Pohto, P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone Naunyn-Schmiedebergs Arch. Pharmacol. 1992, 346, 262-266
97. Keranen, T.; Gordin, A.; Karlsson, M.; Korpela, K.; Pentikainen, P. J.; Rita, H.; Schultz, E.; Seppala, L.; Wikberg, T. Inhibition of soluble catechol- O -methyltransferase and single dose pharmacokinetics after oral and intraveneous administration of entacapone Eur. J. Clin. Pharmacol. 1994, 46, 151-157
98. Novaroli, L.; Doulakas, G. B.; Reist, M.; Rolando, B.; Fruttero, R.; Gasco, A.; Carrupt, P.-A. The lipophilicity behaviour of three catechol-O-methyltransferase (COMT) inhibitors and simple analogues Helv. Chim. Acta 2006, 89, 144-152
99. Savolainen, J.; Forsberg, M.; Taipale, H.; Mannistö, P. T.; Järvinen, K.; Gynther, J.; Jarho, P.; Järvinen, T. Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone Drug Dev. Res. 2000, 49, 238-244
100. Wikberg, T.; Vuorela, A.; Ottoila, P.; Taskinen, J. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans Drug Metab. Dispos. 1993, 21, 81-92
101. Bäckström, R. J.; Kalevi, E.; Heinola, K. E.; Honkanen, E. J.; Kaakkola, S. K.; Kairisalo, P. J.; Linden, I.-B. Y.; Männistö, P. T.; Nissinen, E. A. O.; Pohto, P.; Pippuri, A. K.; Pystynen, J. J. Pharmacologically active catechol derivatives. U.S. Patent US5446194, 1995.
102. Aho, P.; Pohto, P.; Linden, I.-B. Y.; Bäckström, R. J.; Honkanen, E.; Nissinen, E. New use of catechol-o-methyl transferase (comt) inhibitors and their physiologically acceptable salts and esters. European Patent EP0323162, 1989.
103. Linden, I.-B. Y.; Ranta, S. H.; Heinonen, E. O.; Kaakkola, S. K.; Nissinen, E. A. O.; Pohlo, P. Use of catechol-o·methyl transferase (COMT) inhibitors as anti-cancer agents. U.K. Patent GB2220569, 1990.
104. Aperia, A. C.; Linden, I.-B. Y. Use of COMT Inhibitors for the manufacture of a medicament for the prevention of Diabetic Vascular Dysfunctions. International Patent WO199827973, 1998.
105. Aho, P.; Linden, I.-B. Y. Use of COMT inhibitors as analgesics. International Patent WO200168083, 2001.
106. Ellimen, J.; Karvinen, J.; Vahteristo, M. Treatment of restless leg syndrome. International Patent WO2006051154, 2006.
107. Nissinen, H.; Vahteristo, M.; Kuoppamaki, M.; Ellmen, J.; Leionen, M. Treatment of symptoms of motor dysfunction. International Patent WO2007034024, 2007.
108. Eremadzadeh, E.; Koskinen, L.; Kaakkola, S. K. Computerized rotometer apparatus for recording circling behaviour Methods Find. Exp. Clin. Pharmacol. 1989, 11, 399-407
109. Bernauer, K.; Borgulya, J.; Bruderer, H.; Da Prada, M.; Zürcher, G. Catechol derivatives. U.S. Patent US5236952, 1993.
110. Borgulya, J.; Da Prada, M.; Dingemanse, J.; Scherschlicht, R.; Schlappi, B.; Zürcher, G. Ro 40-7592. Catechol- O -methyltransferase (COMT) inhibitor Drugs Future 1991, 16, 719-721
111. Kaakkola, S.; Wurtman, R. J. Effects of COMT inhibitors on striatal dopamine metabolism a microdialysis study Brain Res. 1992, 587, 241-249
112. Zürcher, G.; Dingemanse, J.; Da Prada, M. Potent COMT inhibition by Ro40-7592 in the periphery and in the brain: preclinical and clinical findings Adv. Neurol. 1993, 60, 641-647
113. Zürcher, G.; Keller, H. H.; Kettler, R.; Borgulya, J.; Bonetti, E. P.; Eigenmann, R.; Da parada, M. Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol O-methyltransferase: a pharmacological study in rats Adv. Neurol. 1990, 53, 497-503
114. Moreau, J. L.; Borgulya, J.; Jenck, F.; Martin, J. R. Tolcapone: A potential new antidepressant detected in a novel animal model of depression Behav. Pharmacol. 1994, 5, 344-350
115. Männistö, P. T.; Lang, A.; Rauhala, P.; Vasar, E. Beneficial effects of co-administration of catechol O-methyltransferase inhibitors and L-dihydroxypheylalanine in rat models of depression Eur. J. Pharmacol. 1995, 274, 229-233
116. Maj, J.; Rogóz, Z.; Skuza, G.; Sowinska, H.; Superata, J. Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinsons disease J. Neural Transm.: Parkinsons Dis. Dementia Sect. 1990, 2, 101-112
117. Törnwall, M.; Mannistö, P. T. Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission Pharmacol. Toxicol. 1991, 69, 64-70
118. Olanow, C. W. Tolcapone and hepatotoxic effects Arch. Neurol. 2000, 57, 263-267
119. Assal, F.; Spahr, L.; Hadengue, A.; Rubbici-Brandt, L.; Burkhard, P. R. Tolcapone and fulminant hepaptitis Lancet 1998, 352, 958
120. Jorga, K. M.; Fotteler, B.; Heizmann, P.; Gasser, R. Metabolism and excretion of tolcapone, a novel inhibitor of catechol O-methyltransferase Br. J. Clin. Pharmacol. 1999, 48, 513-520
121. Smith, K. S.; Smith, P. L.; Heady, T. N.; Trugman, J. M.; Harman, W. D.; McDonald, T. L. In vitro metabolism of tolcapone to reactive intermediates relevance to tolcapone liver toxicity Chem. Res. Toxicol. 2003, 16, 123-128
122. Haasio, K.; Koponen, A.; Pentilla, K. E.; Nissinen, E. Effects of entacapone and tolcapone on mitochondrial membrane potential Eur. J. Pharmacol. 2002, 453, 21-26
123. Nissinen, E.; Kaheinen, P.; Pentilla, K. E.; Kaivola, K.; Linden, I. B. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinsons disease, does not impair mitochondrial energy production Eur. J. Pharmacol. 1997, 340, 287-294
124. Korlipara, L. P.; Cooper, J. M.; Schapira, A. H. Differencies in toxicity of catechol O-methyltransferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells Neuropharmacology 2004, 56, 562-569
125. Benes, J.; Soares-da-Silva, P.; Learmonth, D. Substituted 2-Phenyl-l-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical composition containing them. International Patent WO200037423, 2000.
126. Learmonth, D. A.; Vieira-Coelho, M. A.; Benes, J.; Alves, P. C.; Borges, N.; Freitas, A. P.; Soares-da-Silva, P. Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol- O -methyltransferase J. Med. Chem. 2002, 45, 685-695
127. Palma, P. N.; Bonifácio, M. J.; Loureiro, A. I.; Wright, L. C.; Learmonth, D. A.; Soares-da-Silva, P. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor Drug Metab. Dispos. 2003, 31, 250-258
128. Learmonth, D.; Soares-da-Silva, P. Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them. International Patent WO200198251, 2001.
129. Learmonth, D. A.; Palma, P. N.; Vieira-Coelho, M. A.; Soares-da-Silva, P. Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase J. Med. Chem. 2004, 47, 6207-6217
130. Bonifácio, M. J.; Archer, M.; Rodrigues, M. L.; Matias, P. M.; Learmonth, D. A.; Carrondo, M. A.; Soares-Da-Silva, P. Kinetics and crystal structure of catechol-O-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application Mol. Pharmacol. 2002, 62, 795-805
131. Kiss, L. E.; Ferreira, H. S.; Torrão, L.; Bonifácio, M. J.; Palma, P. N.; Soares-da-Silva, P.; Learmonth, D. A. Discovery of a long-acting, peripherally selective inhibitor of catechol- O -methyltransferase J. Med. Chem. 2010, 53, 3396-3411
132. Palma, P. N.; Bonifácio, M. J.; Loureiro, A. I.; Soares-da-Silva, P. Computation of the binding affinities of catechol- O -methyltransferase inhibitors: Multisubstate relative free energy calculations J. Comput. Chem. 2012, 33, 970-986
133. Bonifácio, M. J.; Torrão, L.; Loureiro, A. I.; Wright, L. C.; Soares-da-Silva, P. Opicapone: Characterization of a novel peripheral long-acting catechol- O -methyltransferase inhibitior Parkinsonism Relat. Disord. 2012, 18 (S2) S125
134. Bonifácio, M. J.; Sutcliffe, J. S.; Torrão, L.; Wright, L. C.; Soares-da-Silva, P. Brain and peripheral levodopa pharmacokinetics in the cynomolgus monkey following administration of opicapone, a novel catechol- O -methyltransferase inhibitor Parkinsonism Relat. Disord. 2012, 18 (S2) S125
135. Takehiro, I.; Toshihiro, N.; Hitoshi, I.; Nobuyuki, T.; Hideyuki, M. Novel catechol derivative, pharmaceutical composition containing the same, and uses of those. International Patent WO2007063789, 2007.
136. Pérez, R. A.; Fernández-Alvarez, E.; Nieto, O.; Piedrafita, F. J. Dihydroxynitrobenzaldehydes and hydroxymethoxynitrobenzaldehydes: Synthesis and biological activity as catechol-O-methyltransferase inhibitors J. Med. Chem. 1992, 35, 4584-4588
137. Pérez, R. A.; Fernández-Alvarez, E.; Nieto, O.; Piedrafita, F. J. Inhibition of catechol-O-methyltransferase by 1-vinyl derivatives of nitrocatechols and nitroguaiacols. Kinetics of the irreversible inhibition by 3-(3-hydroxy-4-methoxy-5-nitro benzylidene)-2,4-pentanedione Biochem. Pharmacol. 1993, 45, 1973-1981
138. Pérez, R. A.; Fernández-Alvarez, E.; Nieto, O.; Piedrafita, F. J. Kinetics of the reversible tight-binding inhibition of pig liver catechol- O -methyltransferase by [2-(3,4-dihydroxy-2-nitrophenyl) vinyl]phenyl ketone Enzyme Inhib. 1994, 8, 123-131
139. Rivas, E.; de Ceballos, M. L.; Nieto, O.; Fontenla, J. A. In vivo effects of new inhibitors of catechol-O-methyltransferase Br. J. Pharmacol. 1999, 126, 1667-1673
140. Learmonth, D. A.; Bonifácio, M. J.; Soares-da-Silva, P. Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase J. Med. Chem. 2005, 48, 8070-8078
141. Rodrigues, M. L.; Bonifácio, M. J.; Soares-da-Silva, P.; Carrondo, M. A.; Archer, M. Crystallization and preliminary X-ray diffraction studies of a catechol- O -methyltransferase/inhibitor complex Acta Crystallogr. 2005, F61, 118-120
142. Palma, P. N.; Rodrigues, M. L.; Archer, M.; Bonifácio, M. J.; Loureiro, A. I.; Learmonth, D. A.; Carrondo, M. A.; Soares-da-Silva, P. Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase. Interactions with the active site and regioselectivity of O -methylation Mol. Pharmacol. 2006, 70, 143-153
143. Pystynen, J.; Luiro, A.; Lotta, T.; Ovaska, M.; Vidgren, J. New catechol derivatives. International Patent WO199637456, 1996.
144. Ahlmark, M.; Din Belle, D.; Kauppala, M.; Luiro, A.; Pajunen, T.; Pystynen, J.; Tiainen, E.; Vaismaa, M. Catechol O-methyltransferase activity inhibiting compounds. International Patent WO2013175053, 2013.
145. Takehiro, I.; Inoue, H.; Kobayashi, S.; Yoshida, M.; Shiohara, H.; Ueno, Y.; Nobuyuki, T. Novel catechol derivative, pharmaceutical composition containing the same, and use of the catechol derivative and use of the pharmaceutical composition. International Patent WO2009081891, 2009.
146. Hiroaki, S.; Satoko, K.; Hitoshi, I.; Masako, Y.; Yasunori, U.; Nobuyuki, T. Novel catechol derivative, pharmaceutical composition containing the same, and uses of those. International Patent WO2009081892, 2009.
147. Takehiro, I.; Satoko, K.; Hitoshi, I.; Yasunori, U.; Masako, Y.; Nobuyuki, T. Novel catechol derivative, pharmaceutical composition containing the same, and use of the catechol derivative and use of the pharmaceutical composition. International Patent WO2010001821, 2010.
148. Pystynen, J.; Ovaska, M.; Vidgren, J.; Lotta, T.; Yliperttula-ikonen, M. Coumarin derivatives with COMT inhibiting activity. International Patent WO200202548, 2002.
149. Bäckström, R.; Pystynen, J.; Lotta, T.; Ovaska, M.; Taskinen, J. Derivatives of naphthalene with COMT inhibiting activity. International Patent WO200222551, 2002.
150. Ahlmark, M.; Bäckström, R.; Luiro, A.; Pystynen, J.; Tiainen, E. New pharmaceutical compounds. International Patent WO2007010085, 2007.
151. Rautio, J.; Leppänen, J.; Lehtonen, M.; Laine, K.; Koskinen, M.; Pystynen, J.; Savolainen, J.; Sairanen, M. Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol- O -methyltransferase inhibitor Bioorg. Med. Chem. Lett. 2010, 20, 2614-2616
152. Belleau, B.; Burba, J. Tropolones: A unique class of potent non-competitive inhibitors of S-adenosylmethionine-catechol methyltransferase Biochim. Biophys. Acta 1961, 54, 195-196
153. Broch, O. J. The in vivo effect of tropolone on noradrenaline metabolism and catechol-O-methyltransferase activity in the striatum of the rat Acta Pharmacol. Toxicol. 1973, 33, 417-428
154. Borchardt, R. T. Catechol-O-methyltransferase. 4. In vitro inhibition by 3-hydroxy-4-pyrones, 3-hydroxy-2-pyridones and 3-hydroxy-4-pyridones J. Med. Chem. 1973, 16, 581-583
155. Wolkenberg, S.; Barrow, J. C.; Poslusney, S. T.; Harrison, S. T.; Trotter, B. W.; Mulhearn, J.; Nanda, K. K.; Manley, P. J.; Zhao, Z.; Scubert, J. W.; Kett, N.; Zartman, A. Inhibitors of Catechol-O-methyltransferase and their use in the treatment of psychotic disorders. International Patent WO2011109254, 2011.
156. Wolkenberg, S.; Barrow, J. C.; Harrison, S. T.; Trotter, B. W.; Nanda, K. K.; Manley, P. J.; Zhao, Z. Inhibitors of catechol- O -methyltransferase and their use in the treatment of psychotic disorders. International Patent WO2011109261, 2011.
157. Wolkenberg, S.; Harrison, S. T.; Barrow, J. C.; Zhao, Z.; Kett, N.; Zartman, A. Inhibitors of catechol-O-methyltransferase and their use in the treatment of psychotic disorders. International Patent WO2011109267, 2011.
158. Brevitt, S. E.; Tan, E. W. Synthesis and in vitro evaluation of two progressive series of bifunctional polyhdroxybenzamide catechol-O-methyltransferase inhibitors J. Med. Chem. 1997, 40, 2035-2039
159. Bailey, K.; Tan, E. W. Synthesis and evaluation of bifunctional nitrocatechol inhibitors of pig liver catechol-O-methyltransferase Bioorg. Med. Chem. 2005, 13, 5740-5749
160. Masjost, B.; Ballmer, P.; Borroni, E.; Zürcher, G.; Winkler, F. K.; Jakob-Roetne, R.; Diederich, F. Structure-based design, synthesis, and in vitro evaluation of bisubstrate inhibitors for catechol O-methyltransferase (COMT) Chem. - Eur. J. 2000, 6, 971-982
161. Lerner, C.; Ruf, A.; Gramlich, V.; Masjost, B.; Zürcher, G.; Jakob-Roetne, R.; Borroni, E.; Diederich, F. X-ray crystal structure of a bisubstrate inhibitor bound to the enzyme catechol- O -methyltransferase: A dramatic effect of inhibitor preorganization on binding affinity Angew. Chem., Int. Ed. 2001, 40, 4040-4042
162. Lerner, C.; Masjost, B.; Ruf, A.; Gramlich, V.; Jakob-Roetne, R.; Zürcher, G.; Borroni, E.; Diederich, F. Bisubstrate inhibitors for the enzyme catechol- O -methyltransferase (COMT): Influence of inhibitor preorganisation and linker length between two substrate moieties on binding affinity Org. Biomol. Chem. 2003, 1, 42-49
163. Paulini, R.; Lerner, C.; Jakob-Roetne, R.; Zürcher, G.; Borroni, E.; Diederich, F. Bisubstrate inhibitors of the enzyme catechol-O-methyltransferase (COMT): Efficient inhibition despite the lack of a nitro group Chem. Biochem. 2004, 5, 1270-1274
164. Diedrich, F.; Jakob-Roetne, R.; Lerner, C.; Paulini, R. COMT inhibitors. International Patent WO2005058228, 2005.
165. Ellermann, M.; Lerner, C.; Burgy, G.; Ehler, A.; Bissantz, C.; Jakob-Roetne, R.; Paulini, R.; Allemann, O.; Tissot, H.; Grunstein, D.; Stihle, M.; Diederich, F.; Rudolph, M. G. Catechol- O -methyltransferase in complex with substituted 3′-deoxyribose bisubstrate inhibitors Acta Crystallogr. D: Biol. Crystallogr. 2012, 68, 253-260
166. Ellermann, M.; Paulini, R.; Jakob-Roetne, R.; Lerner, C.; Borroni, E.; Roth, D.; Ehler, A.; Schweizer, W. B.; Schlatter, D.; Rudolph, M. G.; Diederich, F. Molecular recognition at the active site of catechol-O-methyltransferase (COMT): Adenine replacements in bisubstrate inhibitors Chemistry 2011, 17, 6369-6381
167. Lanier, M.; Ambrus, G.; Cole, D. C.; Davenport, R.; Ellery, J.; Fosbeary, R.; Jennings, A. J.; Kadotani, A.; Kamada, Y.; Kamran, R.; Matsumoto, S.-I.; Mizukami, A.; Okubo, S.; Okada, K.; Saikatendu, K.; Walsh, L.; Wu, H.; Hixon, M. S. A fragment-based approach to identifying S-adenosyl-L-methionine -competitive inhibitors of catechol- O -methyl transferase (COMT) J. Med. Chem. 2014, 57, 5459-5463
168. Leppänen, J.; Huuskonen, J.; Savolainen, J.; Nevalainen, T.; Taipale, H.; Vepsäläinen, J.; Gynther, J.; Järvinen, T. Synthesis of a water-soluble prodrug of entacapone Biorg. Med. Chem. Lett. 2000, 10, 1967-1969
169. Leppänen, J.; Savolainen, J.; Nevalainen, T.; Forsberg, M.; Huuskonen, J.; Taipale, H.; Gynther, J.; Mannistö, P. T.; Järvinen, T. Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs J. Pharm. Pharmacol. 2001, 53, 1489-1498
170. Savolainen, J.; Leppänen, J.; Forsberg, M.; Taipale, H.; Nevalainen, T.; Huuskonen, J.; Gynther, J.; Mannistö, P. T.; Järvinen, T. Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl and N,N-dialkyl-carbamate esters of entacapone Life Sci. 2000, 67, 205-206
171. Leppänen, J.; Huuskonen, J.; Nevalainen, T.; Gynther, J.; Taipale, H.; Järvinen, T. Design and synthesis of a novel L-Dopa-entacapone codrug J. Med. Chem. 2002, 45, 1379-1382
172. Gordin, A.; Tarpila, S.; Kaakkola, S.; Nissinen, E.; Schultz, E.; Bäckström, R. Inhibition of soluble COMT activity in healty volunteers by OR-462, a potential drug for Parkinsons disease Neurol. India 1989, 37 (suppl) 286
173. Borges, N. Tolcapone in Parkinsons disease: Liver toxicity and clinical efficacy Expert Opin. Drug Saf. 2005, 4, 69-73
174. Almeida, L.; Soares-da-Silva, P. Pharmacokinetics and pharmacodynamics of BIA3-202, a novel COMT inhibitor, during first administration to humans Drugs R&D 2003, 4, 207-217
175. Silveira, P.; Vaz-Da-Silva, M.; Almeida, L.; Maia, J.; Falcão, A.; Loureiro, A.; Torrão, L.; Machado, R.; Wright, L. C.; Soares-da-Silva, P. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide Eur. J. Clin. Pharmacol 2003, 59, 603-609
176. Rocha, J. F.; Almeida, L.; Falcao, A.; Palma, P. N.; Loureiro, A. I.; Pinto, R.; Bonifacio, M. J.; Wright, L. C.; Nunes, T.; Soares-da-Silva, P. Opicapone: A short lived and very long acting novel catechol- O -methyltransferase inhibitor following multiple-dose administration in healthy subjects Br. J. Clin. Pharmacol. 2013, 76, 763-775
177. Rocha, J. F.; Falcão, A.; Santos, A.; Pinto, R.; Lopes, N.; Nunes, T.; Wright, L. C.; Vaz-da-Silva, M.; Soares-da-Silva, P. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations Eur. J. Clin. Pharmacol. 2014, 70, 1059-1071
178. Lees, A.; Costa, R.; Oliveira, C.; Lopes, N.; Nunes, T.; Soares-da-Silva, P. The design of a double-blind, placebo-controlled, multi-national phase-III trial in patients with Parkinsons disease and end-of-dose motor fluctuations: Opicapone superiority vs. placebo Mov. Disord. 2012, 27, S127
179. Ferreira, J. J.; Rocha, J. F.; Santos, A.; Nunes, T.; Soares-da-Silva, P. The design of a double-blind, placebo- and active-controlled, multi-national phase-III trial in patients with Parkinsons disease and end-of-dose motor fluctuations: Opicapone superiority vs. placebo and non-inferiority vs. entacapone Mov. Disord. 2012, 27, S118